US7214506 — Method for treating onychomycosis
Method of Use · Assigned to Kaken Pharmaceutical Co Ltd · Expires 2026-02-22 · 0y expired
What this patent protects
This patent protects a method for evaluating the effect of an antimicrobial agent, specifically for onychomycosis treatment.
USPTO Abstract
A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.
Drugs covered by this patent
- Jublia (EFINACONAZOLE) · Bausch Health
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-281 |
— | Jublia |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.